Lindsay Burns

Source: Wikipedia, the free encyclopedia.

Lindsay Burns
Personal information
Born1965 (age 58–59)
Big Timber, Montana, U.S.
Medal record
Women's rowing
Representing  United States
Olympic Games
Silver medal – second place 1996 Atlanta Lwt double sculls
World Rowing Championships
Gold medal – first place 1987 Copenhagen Lwt four
Silver medal – second place 1990 Tasmania Lwt double sculls
Silver medal – second place 1991 Vienna Lwt double sculls
Bronze medal – third place 1994 Indianapolis Lwt double sculls

Lindsay H. Burns (born 1965) is an American

pharmaceutical company Cassava Sciences[2] and married to its CEO Remi Barbier
.

As of July 2022, Cassava Sciences and papers published by Burns are under investigation; Cassava denies any wrongdoing.[3][4][5][6][7]

Personal life

Burns was born in 1965[8] and raised in Big Timber, Montana.[9] She graduated from Harvard University in 1987.[9] In 1991, she obtained a PhD in neuroscience from University of Cambridge[9] on a thesis titled Functional interactions of limbic afferents to the striatum and mesolimbic dopamine in reward-related processes,[10] which was supervised by Barry Everitt and Trevor Robbins.[11][12]

Burns worked as a research fellow in psychobiology at McLean Hospital in Belmont, Massachusetts.[9] She joined Cassava Sciences in 2002 and became senior vice president of neuroscience in 2021.[13]

Burns is married to Remi Barbier, the CEO and founder of Cassava Sciences.[14][15][16]

Rowing career

Burns started competitive rowing soon after entering Harvard.

quad sculls (heavyweight) category[1] and she won the European Rowing Championships at Lucerne in 1995 with Teresa Bell.[17] She was an alternate rower at the 1992 Summer Olympics in Barcelona, Spain.[citation needed
]

She teamed up again with Teresa Bell at the 1996 Summer Olympics in Atlanta, United States, and won a silver medal in the Lightweight Double Sculls.[1] In 2006, she was inducted into the Harvard Sports Hall of Fame.[14] In 2016, she was inducted into the National Rowing Foundation Hall of Fame.[18]

Scientific works

Burns's first research was on the effect of neurokinin A on brain functions in rats. Her first paper in 1988, written with Ann E. Kelley, reported that neurokinin A in the ventral tegmental area modifies dopamine circuits to induce behavioral changes.[19] She continued her PhD research on the role of dopamine and the limbic system.[11][12][10][20][21] During her post-doc at McLean Hospital, she focused on neurodegenerative diseases, specifically, transplantation of pig neural cells into rat brain as a possible treatment of Parkinson's or Huntington's disease.[22] Further research indicated possible use in humans.[23] While working for a biotech company later acquired by Elan Pharmaceuticals, she published the effects of ziconotide in a rat model of spinal cord ischemia.[24]

In 2005, she published a series of papers on Oxytrex and related research with ultra-low doses of certain (

opioid antagonists) to enhance analgesia and prevent opioid-induced hyperalgesia, opioid tolerance and substance dependence.[25][26][27][28]

Since 2006, Burns has collaborated with Hoau-Yan Wang at the City University of New York,[29] who had been investigating Alzheimer's disease. Previously identifying filamin A (FLNA) for its role in regulating opioid receptor signaling,[citation needed] Burns and Wang then identified FLNA as a critical protein in enabling Abeta42's signaling through the alpha 7 nicotinic acetylcholine receptor to induce Alzheimer's disease pathology.[30][31][32]

FLNA, simufilam and Alzheimer's disease

In 2008, Burns, Wang and Maya Frankfurt published in

cytoplasmic protein that maintains normal cell shape and division. In 2010, Burns and Wang announced a novel analgesic" which they named PTI-609 (PTI for Pain Therapeutics, Inc., the former name of Cassava Sciences) and stated that the molecule binds to FLNA as well as activating mu opioid receptors.[35]

In 2012, they published in The Journal of Neuroscience a novel compound PTI-125 that binds to FLNA similarly to naloxone and naltrexone.[36] With PTI-125, they stated that FLNA aberrantly links to the alpha 7 nicotinic receptor, enabling signaling of Abeta42 to hyperphosphorylate tau.[31][36]

In 2017, they reported in

United States Adopted Names (USAN) gave the drug name for PTI-125 as simufilam in 2020;[39] as of 2022, it is in Phase III clinical trials
.

Research controversies

Further information: Cassava Sciences § Allegations of research fraud

As of July 2022, Cassava Sciences and papers published by Burns and Wang are under investigation by the

U.S. Justice Department; Cassava denies any wrongdoing.[3][4][5] The U.S. Securities and Exchange Commission (SEC), the U.S. National Institutes of Health (NIH), and City University of New York (CUNY) were also investigating allegations of manipulated data.[5]

In October 2023, CUNY reported that they could obtain none of Wang's original data, which meant that they were unable to either prove or disprove allegations that the images were improperly manipulated.[40][41] According to The Wall Street Journal, the CUNY report stated that Burns shared with Wang some responsibility "for errors and misconduct".[41]

References

  1. ^ a b c "Biography: Lindsay Burns". Olympics. International Olympic Committee. Retrieved May 2, 2022.
  2. ^ Keown, Alex (April 19, 2022). "Cassava Faces Renewed Speculation Over Experimental Alzheimer's Drug". BioSpace. Retrieved May 9, 2022.
  3. ^ a b Taylor, Marisa; Spector, Mike (July 27, 2022). "Exclusive: Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say". Reuters. Retrieved July 31, 2022.
  4. ^ a b "Cassava Sciences Responds to Media Reports" (Press release). Cassava Sciences. July 27, 2022. Retrieved August 16, 2022.
  5. ^
    ISSN 0099-9660
    . Retrieved April 29, 2022.
  6. ISSN 0362-4331
    . Retrieved April 28, 2022.
  7. ^ "The Cassava Sciences saga: Short sellers, 'gaming' the FDA, and the damaging ripple effects".
  8. ^ "Lindsay Burns". World Rowing.
  9. ^ a b c d e "Harvard at the Olympics". Harvard Magazine. Retrieved May 3, 2022.
  10. ^
    OCLC 556753196
    .
  11. ^
    S2CID 4032314
    .
  12. ^
    S2CID 28351013
    .
  13. ^ "Lindsay H Burns, Cassava Sciences Inc: Profile and Biography". Bloomberg.com. Retrieved May 3, 2022.
  14. ^ a b c "Lindsay Burns Barbier '87". www.harvardvarsityclub.org. Retrieved May 2, 2022.
  15. ^ Keefe, Patrick Radden (January 15, 2022). "Jordan Thomas's Army of Whistle-Blowers". The New Yorker. Archived from the original on July 22, 2022. Retrieved April 29, 2022.
  16. ^ Feuerstein, Adam (April 5, 2022). "Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer's drug studies". STAT. Retrieved April 30, 2022.
  17. ^ "Rowing News". July 16–29, 1995.
  18. ^ "The National Rowing Foundation Announces the 2016 Inductees to the National Rowing Hall of Fame". January 26, 2016.
  19. S2CID 20941335
    .
  20. PMID 8652073
    .
  21. PMID 10066290
    .
  22. S2CID 7344970
    .
  23. S2CID 23945411
    .
  24. PMID 10436454
    .
  25. PMID 15943961
    .
  26. S2CID 13270740
    .
  27. S2CID 25513761
    .
  28. ISBN 978-1-58829-881-2
    , retrieved May 3, 2022
  29. PMID 16967511
    .
  30. S2CID 9933756
    .
  31. ^
    PMID 34295950
    .
  32. S2CID 245570217
    .
  33. PMID 18253501
    .
  34. PMID 19172190
    .
  35. PMID 20726836
    .
  36. ^
    PMID 22815492
    .
  37. S2CID 207163555
    .
  38. PMID 33297460
    .
  39. ^ "Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name 'sumifilam' by USAN". Global Newswire (Press release). Cassava Sciences. August 24, 2020. Retrieved May 3, 2022.
  40. doi:10.1126/science.adl3444
    .
  41. ^
    ProQuest 2876611078
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lindsay_Burns&oldid=1220940284"